Focus Partners Wealth
CRSP icon

Focus Partners Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Focus Partners Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$322K Buy
5,903
+1,343
+29% +$70.8K ﹤0.01% 2230
2026
Q1 		$217K Buy
4,560
+293
+7% +$15.5K ﹤0.01% 2380
2025
Q4 		$226K Sell
4,267
-2,327
-35% -$139K ﹤0.01% 2389
2025
Q3 		$444K Buy
6,594
+1,170
+22% +$67.2K ﹤0.01% 1661
2025
Q2 		$264K Buy
+5,424
New +$210K ﹤0.01% 1746
2025
Q1 		– Sell
-6,082
Closed -$239K – 1933
2024
Q4 		$239K Buy
+6,082
New +$287K ﹤0.01% 1654
2024
Q3 		– Sell
-3,973
Closed -$215K – 1597
2024
Q2 		$215K Buy
+3,973
New +$230K ﹤0.01% 1146

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Focus Partners Wealth's CRSP Position: Q2 2026 in Review

Focus Partners Wealth increased its CRISPR Therapeutics (CRSP) stake by 29% in Q2 2026, buying an estimated $70.8K and bringing the position to 5,903 shares worth $322K. The position accounts for ﹤0.01% of the portfolio, ranked #2230.

Focus Partners Wealth first reported a position in CRSP in Q2 2024 and has held it in 7 quarters since. The position peaked at $444K in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Focus Partners Wealth held 5,903 shares of CRISPR Therapeutics worth $322K as of Q2 2026.
  • Focus Partners Wealth bought 1,343 CRISPR Therapeutics shares in Q2 2026, an estimated $70.8K.
  • CRISPR Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2230 holding.
  • Focus Partners Wealth first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Focus Partners Wealth's CRISPR Therapeutics position peaked at $444K in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.